Article
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2018
Song Kyung-A, Hosono Yasuyuki, Turner Crystal, Jacob Sheeba, Lochmann Timothy L, Murakami Yoshiko, Patel Neha U, Ham Jungoh, Hu Bin, Powell Krista M, Coon Colin M, Windle Brad E, Oya Yuko, Koblinski Jennifer E, Harada Hisashi, Leverson Joel D, Souers Andrew J, Hata Aaron N, Boikos Sosipatros, Yatabe Yasushi, Ebi Hiromichi, Faber Anthony C
Abstract excerpt
Purpose: EGFR inhibitors (EGFRi) are effective against EGFR-mutant lung cancers. The efficacy of these drugs, however, is mitigated by the outgrowth of resistant cells, most often driven by a secondary acquired mutation in EGFR, T790M We recently demonstrated that T790M can arise de novo during treatment; it follows that one potential therapeutic strategy to thwart resistance would be identifying and eliminating...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.